Abstract 1751P
Background
Standardized incidence and mortality rates are the default measures to describe cancer trends while survival assesses advances in cancer detection and treatment. Mortality compounds both incidence and survival but does not fully address age at death or long-term survival, both essential to quantify the cancer burden on society.
Methods
Using Swedish National Cancer and Cause of Death Register data together with publicly accessible projections of life expectancy, we calculated years of life lost (YLL) as the difference between age at cancer death and expected age at death for an individual of the corresponding age, sex, and birth year in the general population. All adults (18-95 years) with death reported as caused by one of the 10 solid tumors causing most deaths (lung, colorectal, prostate, pancreatic, breast, hepatobiliary, urinary, central nervous system, gastric cancer, or melanoma) in Sweden from 2010-2019, were included.
Results
When YLL were related and compared to mortality estimates in 2019 (Table), lung cancer (43,152 YLL) and colorectal cancer (32,340 YLL) remained at the top. Pancreatic cancer was up-ranked from 4th to 3rd place (22,592 YLL) and breast cancer from 5th to 4th place (21,810 YLL), while prostate cancer was down-ranked from 3rd to 5th place (17,380 YLL). In the table, a traditional approach ranking the 10 most common causes of cancer death in number of deaths and mortality rate (A), and new ranking using years of life lost approach (B), Sweden 2019.
Table: 1751P
A. Traditional approach | B. Years of life lost approach | ||||
Cancer site | Deaths | Mortality rate | Rank | Years of life lost | New rank |
Lung | 3144 | 38.7 | 1 | 43152 | 1 |
Colorectal | 2543 | 31.3 | 2 | 32340 | 2 |
Prostate | 2063 | 25.4 | 3 | 17380 | 5 |
Pancreatic | 1600 | 19.7 | 4 | 22592 | 3 |
Breast | 1335 | 16.5 | 5 | 21810 | 4 |
Hepatobiliary | 998 | 12.3 | 6 | 14568 | 6 |
Urinary | 740 | 9.1 | 7 | 7435 | 8 |
Central nervous system | 548 | 6.7 | 8 | 11628 | 7 |
Gastric | 510 | 5.8 | 9 | 7159 | 9 |
Melanoma skin | 472 | 6.3 | 10 | 6973 | 10 |
Assessing YLL trends over the period from 2010-2019, women consistently lost more life years due to lung and pancreatic cancer than men. A downward trend in colorectal cancer mortality was reflected as a YLL decline only among women but not men.
Conclusions
Although all vital statistics have inborn advantages and disadvantages, this study demonstrates that YLL is simple to calculate, intuitive to interpret, and is as a meaningful measure to be added to the statistical toolbox box when presenting and comparing cancer trends within and between populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Region Stockholm (grant number: FoUI-963792).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23